Israël - hébreu - Ministry of Health

abic marketing ltd, israel - pemetrexed - אבקה להכנת תמיסה מרוכזת לעירוי - pemetrexed 1000 mg - pemetrexed

Israël - hébreu - Ministry of Health

abic marketing ltd, israel - pemetrexed - אבקה להכנת תמיסה מרוכזת לעירוי - pemetrexed 500 mg - pemetrexed

Israël - hébreu - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

Israël - hébreu - Ministry of Health

taro international ltd, israel - pemetrexed - אבקה להכנת תמיסה מרוכזת לעירוי - pemetrexed 100 mg/vial - pemetrexed

Israël - hébreu - Ministry of Health

taro international ltd, israel - pemetrexed - אבקה להכנת תמיסה מרוכזת לעירוי - pemetrexed 1000 mg/vial - pemetrexed

Israël - hébreu - Ministry of Health

taro international ltd, israel - pemetrexed - אבקה להכנת תמיסה מרוכזת לעירוי - pemetrexed 500 mg/vial - pemetrexed

Israël - hébreu - Ministry of Health

padagis israel pharmaceuticals ltd, israel - lactulose - סירופ - lactulose 66.7 g / 100 ml - lactulose - lactulose - constipation. acute and chronic hepatic encephalopathy.

Israël - hébreu - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israël - hébreu - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israël - hébreu - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob